SuperworthCytek Biosciences CTKB
- Market cap
- $726.6M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 3.5×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $206.7M
- +5% on a year ago
- Net margin
- −39.0%
- Free cash flow yield
- −1.7%
Cytek Biosciences trades at 3.5× sales. Its trailing earnings are negative, so it has no PE. Revenue was $206.7M over the last twelve months, up 5% on a year earlier with a −39% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $48M+19% | $58.2M+21% | $44.9M+21% | $46.6M−6% | $51.5M+7% | $57.5M−1% | $41.5M−8% | $45.6M−2% | $52.3M+2% | $62.1M+8% | $44.1M+7% | $48.1M+6% | |
| Cost of revenue | $20.8M+53% | $25.2M+33% | $21.8M+36% | $21.2M−2% | $22.5M+8% | $23.8M−5% | $21.3M−3% | $21.7M+3% | $24.7M+10% | $29.3M+23% | $22.9M+7% | $19.8M−9% |
| Gross profit | $27.2M+1% | $33M+13% | $23M+9% | $25.4M−10% | $29M+7% | $33.7M+2% | $20.2M−12% | $23.9M−6% | $27.6M−5% | $32.9M−2% | $21.3M+5% | $28.3M+19% |
| R&D | $11.2M+29% | $10.9M+12% | $9.8M−2% | $10M−18% | $9.9M−12% | $9.7M−11% | $9.7M−1% | $8.8M−12% | $9M−9% | $9M−8% | $9.6M−1% | $9.7M+10% |
| SG&A | $22.4M+33% | $22.3M+14% | $24M+3% | $24M−5% | $23.4M+4% | $20.9M−6% | $25.4M+6% | $25.7M+7% | $27.8M+19% | $29.5M+41% | $30.1M+19% | $30M+17% |
| −$6.4M | −$137K | −$10.7M−12% | −$8.5M−7% | −$4.2M−34% | $3M | −$15M+40% | −$10.6M+25% | −$9.2M+116% | −$5.6M | −$18.5M+23% | −$11.4M+7% | |
| Interest expense | $595K−8% | $394K−43% | $441K−35% | $134K−67% | $119K−80% | −$5.9M | $291K−34% | $414K+209% | $494K+315% | −$725K−88% | $262K−10% | $281K−32% |
| Pre-tax income | −$4.2M | $4.1M−0% | −$9M−1% | −$7.2M+9% | $157K | $10.3M+151% | −$11.3M+25% | −$6.8M−6% | −$7.8M | −$4M | −$17.4M+54% | −$11.6M+72% |
| $2.3M+914% | −$1.4M | −$2.8M+27% | $3.2M | −$784K | $680K | $136K | −$1.2M | −$2.3M+192% | $40M+5789% | $1.5M+998% | $515K | |
| Net income | −$6.5M | $5.5M+56% | −$6.2M−9% | −$10.4M+138% | $941K | $9.6M+75% | −$11.4M+85% | −$5.6M−47% | −$5.5M | −$44.1M | −$18.9M+66% | −$12.2M+118% |
| −$0.05 | $0.04+33% | −$0.05+0% | −$0.08+167% | $0.01 | $0.07+75% | −$0.09+80% | −$0.04−50% | −$0.04 | −$0.34 | −$0.15+67% | −$0.09+125% | |
| 136.2M−2% | 133.6M−4% | 130.9M−3% | 131.4M−3% | 132.8M−3% | 129.1M−3% | 128.3M−2% | 126.9M−3% | 127.5M−4% | 128.2M−1% | 128.7M+0% | 129.5M+2% |
Revenue: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
R&D: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
SG&A: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Operating income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Income tax: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Net income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
EPS, diluted: 9 periods, Q1 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY20: share-days: the 6-month average less the second quarter's. 4 periods, Q4 FY20 to Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY22: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution. Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Diagnostics & Research nearest Cytek Biosciences' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CTKBCytek Biosciences | $726.6M | n/m | 262× | 3.5× | +5% | −39.0% | |
| NRCNRC Health | $485.1M | 87.7× | 35.1× | 3.5× | −0% | 4.2% | |
| CDNACareDx | $3.6B | 33.4× | 19.1× | 7.8× | +34% | 24.2% | |
| VCYTVeracyte | $3.9B | 34.2× | 66.8× | 6.9× | +17% | 20.4% | |
| BLLNBillionToOne | $5.1B | 166× | 151× | 12.8× | +90% | 9.5% | |
| ICCCImmucell | $93.1M | 128× | 44.0× | 3.0× | +8% | 2.6% | |
| LNTHLantheus | $6.5B | 24.2× | 24.0× | 4.2× | +2% | 17.7% | |
| Peer median | $3.7B | 61.0× | 39.6× | 5.5× | +13% | 13.6% |
More on Cytek Biosciences
Each number over time
- PE ratio
- Price to sales ratio
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .